Estimating clinically meaningful change thresholds for a European Organisation for Research and Treatment of Cancer IL-409 proxy in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: results from the ALPINE trial (NCTNCT03734016) - Patient Guide & Enrollment Help